Intuitive Surgical — Da Vinci Surgical Robot: Dominating the Global Market with Equipment + Consumables

Origin

In 1995, Frederic Moll embarked on his second venture in Silicon Valley. Having previously founded Origin Medsystems, which was acquired by Johnson & Johnson for its traditional laparoscopic equipment, he identified the physical limitations of laparoscopic instruments—specifically their low degree of freedom and restricted 3D field of view. Intuitive Surgical secured a license for military teleoperation robotic arm technology developed by SRI International with funding from the U.S. Department of Defense. The goal was to allow surgeons' fine hand movements to be scaled down and replicated inside the body via robotic arms, while performing minimally invasive surgery through only a few small incisions. The first Da Vinci prototype was completed around 1998, entered clinical use in Europe in 1999, and received FDA 510(k) clearance in 2000, leading to its Nasdaq listing and the start of the commercialization of surgical robots.

Milestones

Turning Points

• In 2000, FDA approval made Da Vinci the world's first legally commercialized surgical robot, marking the leap of military teleoperation technology into hospital procurement.
• In 2003, the reverse acquisition of Computer Motion ended the patent war through a stock-for-stock merger, leaving no comparable competitors in the laparoscopic surgical robot track.
• Around 2010, the proportion of revenue from consumables and services rose rapidly, shifting the business model from selling equipment to a 'razor-and-blade' model of continuous charging based on surgical volume.
• In 2024, the Da Vinci 5, priced at approximately $2 million, initiated a replacement cycle, proving that high-priced flagships can still drive growth in both global installations and consumables.
• In 2026, the collective 'Buy' ratings from Wall Street after a 30% stock price drop validated that the market viewed short-term capital volatility as a correction of a monopoly position rather than a deterioration of fundamentals.

Failures & Pitfalls

• The two-year patent litigation with Computer Motion from 2001 to 2003 severely dragged down the early commercialization pace due to legal costs and management distraction, ultimately requiring a high-premium acquisition to resolve.
• The Ion lung biopsy robot, launched in 2019, saw early volume far below expectations; the surgeon learning curve and the expansion of pulmonology procedures were much slower than laparoscopy, only gaining traction after 2022.
• The 2020 COVID-19 pandemic caused a widespread halt in elective surgeries globally, with annual revenue falling from $4.48 billion in 2019 to approximately $4.36 billion, exposing a high reliance on surgical traffic.
• The single-port SP robot launched in 2018 failed to become a standard in mainstream departments for years due to limited departmental compatibility, and the trial-and-error costs of platform expansion were underestimated by the market.
• In 2026, the company faced price-cutting strategies from domestic competitors like United Imaging and MicroPort MedBot in the Chinese market, leading to rising localization costs and pressure on gross margins.

Core Data

• 2024 Revenue：Approx. $8.4 billion (based on public data, independent verification not performed)
• 2024 Surgical Volume Growth：Approx. 17% (based on public data, independent verification not performed)
• Global Cumulative Installations：Over 9,000 units (based on public data, independent verification not performed)
• Quarterly Surgical Volume：889,000 cases (based on public data, independent verification not performed)
• 2024 Gross Margin：Approx. 66% (based on public data, independent verification not performed)
• Recurring Revenue Proportion：Approx. 80% (based on public data, independent verification not performed)
• Da Vinci 5 Unit Price：Approx. $2 million (based on public data, independent verification not performed)
• Global Surgical Robot Market Share：Approx. 80% (based on public data, independent verification not performed)
• Peak Market Capitalization：Approx. $200 billion (based on public data, independent verification not performed)

Competitors / Peers

Benchmarked peers include Medtronic's Hugo robot, Johnson & Johnson's previously backed Verb Surgical and Ottava (project cancelled in 2023), France's CMR Surgical with Versius, Sweden's Getinge, and Chinese companies like MicroPort MedBot (Toumai), Kangduo Robot, and United Imaging Intelligence. CMR Surgical targets the mid-range market in Europe and Asia with a modular, lightweight design, while MicroPort's Toumai has been winning urology orders at about half the price of Da Vinci since receiving certification in 2022. These competitors currently hold less than 20% of the market combined. The focus of competition has shifted from installation price wars to consumable pricing, surgeon training networks, surgical volume operations, and after-sales response. Da Vinci maintains its moat through its 9,000-unit installed base and approximately 80% recurring revenue, while the domestic camp seeks gaps through government centralized procurement and localized services.